Have a feature idea you'd love to see implemented?
Let us know!
VRDN Viridian Therapeutics Inc
Price (delayed)
$19.775
Market cap
$1.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.3
Enterprise value
$1.39B
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal
Highlights
The equity has soared by 149% YoY and by 34% QoQ
VRDN's quick ratio is up by 35% year-on-year and by 17% since the previous quarter
VRDN's revenue is down by 13% YoY but it is up by 4.9% from the previous quarter
VRDN's gross profit is down by 13% YoY but it is up by 4.9% QoQ
The net income has contracted by 19% YoY and by 13% from the previous quarter
Viridian Therapeutics's debt has increased by 2.6% YoY
Key stats
What are the main financial stats of VRDN
Market
Valuations
Earnings
Shares outstanding
79.21M
Market cap
$1.57B
Enterprise value
$1.39B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.79
Price to sales (P/S)
4,349.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,591.52
Revenue
$302,000
Gross profit
$302,000
Net income
-$257.08M
EBIT
-$253.98M
EBITDA
-$253.24M
Free cash flow
-$197.43M
Per share
Balance sheet
Liquidity
EPS
-$4.3
EPS diluted
-$4.3
Free cash flow per share
-$2.97
Book value per share
$11.07
Revenue per share
$0
TBVPS
$11.62
Total assets
$771.9M
Total liabilities
$64.4M
Debt
$20.52M
Equity
$707.5M
Working capital
$725.99M
Debt to equity
0.03
Current ratio
18.55
Quick ratio
18.21
Net debt/EBITDA
0.71
Margins
Efficiency
Dividend
EBITDA margin
-83,853%
Gross margin
100%
Net margin
-85,127.2%
Operating margin
-93,722.5%
Return on assets
-41.5%
Return on equity
-45.5%
Return on invested capital
-52.7%
Return on capital employed
-34.8%
Return on sales
-84,099.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRDN stock price
How has the Viridian Therapeutics stock price performed over time
Intraday
2.41%
1 week
5.58%
1 month
-9.74%
1 year
-12.07%
YTD
-9.21%
QTD
-13.08%
Financial performance
How have Viridian Therapeutics's revenue and profit performed over time
Revenue
$302,000
Gross profit
$302,000
Operating income
-$283.04M
Net income
-$257.08M
Gross margin
100%
Net margin
-85,127.2%
The operating margin has decreased by 40% YoY and by 8% QoQ
Viridian Therapeutics's net margin has decreased by 36% YoY and by 8% QoQ
The operating income has declined by 22% year-on-year and by 13% since the previous quarter
The net income has contracted by 19% YoY and by 13% from the previous quarter
Growth
What is Viridian Therapeutics's growth rate over time
Valuation
What is Viridian Therapeutics stock price valuation
P/E
N/A
P/B
1.79
P/S
4,349.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,591.52
Viridian Therapeutics's EPS has increased by 16% YoY
The equity has soared by 149% YoY and by 34% QoQ
The price to book (P/B) is 13% less than the 5-year quarterly average of 2.0 and 13% less than the last 4 quarters average of 2.0
The P/S is 16% more than the last 4 quarters average of 3676.8
VRDN's revenue is down by 13% YoY but it is up by 4.9% from the previous quarter
Efficiency
How efficient is Viridian Therapeutics business performance
Viridian Therapeutics's return on invested capital has increased by 40% YoY and by 7% QoQ
Viridian Therapeutics's return on sales has decreased by 35% YoY and by 7% QoQ
The company's return on equity rose by 29% YoY and by 8% QoQ
The return on assets rose by 28% year-on-year and by 7% since the previous quarter
Dividends
What is VRDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRDN.
Financial health
How did Viridian Therapeutics financials performed over time
Viridian Therapeutics's total assets has surged by 135% YoY and by 32% QoQ
The total liabilities has increased by 43% YoY and by 14% QoQ
Viridian Therapeutics's debt is 97% lower than its equity
The equity has soared by 149% YoY and by 34% QoQ
The debt to equity has plunged by 57% YoY and by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.